$TXG
10X Genomics Inc Stock $txg

$txg Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000177078721000009 Filed on February 26, 2021

Income Statement

Concept	2020 Q4	2020 Q1	2019 Q4
Revenue	$112.2M	$71.91M	$75.29M
YoY Change	49.03%	34.21%	48.93%
Cost Of Revenue	$18.90M	$15.11M	$16.60M
YoY Change	13.86%	8.18%	11.41%
Gross Profit	$93.30M	$56.80M	$58.71M
YoY Change	58.92%	43.38%	64.66%
Gross Profit Margin	83.16%	78.99%	77.98%
Selling, General & Admin	$55.10M	$50.39M	$38.80M
YoY Change	42.01%	87.36%	44.24%
% of Gross Profit	59.06%	88.71%	66.09%
Research & Development	$446.6M	$25.99M	$27.90M
YoY Change	1500.72%	73.69%	-47.46%
% of Gross Profit	478.67%	45.76%	47.52%
Depreciation & Amortization	$3.920M	$3.189M	$2.850M
YoY Change	37.54%	207.82%	220.22%
% of Gross Profit	4.2%	5.61%	4.85%
Operating Expenses	$502.0M	$76.68M	$66.80M
YoY Change	651.5%	79.8%	-39.6%
Operating Profit	-$408.7M	-$19.88M	-$8.093M
YoY Change	4950.04%	555.16%	-89.2%
Interest Expense	-$300.0K	$662.0K	$800.0K
YoY Change	-137.5%	-3.22%	-300.0%
% of Operating Profit
Other Income/Expense, Net	$1.200M	-$961.0K	$200.0K
YoY Change	500.0%	69.49%	-300.0%
Pretax Income	-$408.6M	-$20.85M	-$7.000M
YoY Change	5737.14%	478.71%	-90.73%
Income Tax	$7.000M	$300.0K	$100.0K
% Of Pretax Income
Net Earnings	-$415.6M	-$21.14M	-$7.134M
YoY Change	5725.62%	481.49%	-90.55%
Net Earnings / Revenue	-370.41%	-29.4%	-9.48%
Basic Earnings Per Share		-$0.22
Diluted Earnings Per Share	-$3.870M	-$0.22	-$73.96K
COMMON SHARES
Basic Shares Outstanding		96.83M shares
Diluted Shares Outstanding		96.83M shares

Balance Sheet

Concept	2020 Q4	2020 Q1	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$663.6M	$372.4M	$424.2M
YoY Change	56.44%
Cash & Equivalents	$663.6M	$431.9M	$424.2M
Short-Term Investments
Other Short-Term Assets	$29.60M	$7.100M	$8.000M
YoY Change	270.0%
Inventory	$29.96M	$19.36M	$15.27M
Prepaid Expenses
Receivables	$51.21M	$30.85M	$33.37M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$774.4M	$429.7M	$480.8M
YoY Change	61.04%		352.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$72.84M	$52.38M	$48.82M
YoY Change	49.2%		338.76%
Goodwill	$0.00
YoY Change
Intangibles	$22.35M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.324M	$24.75M	$23.94M
YoY Change	-81.93%		1134.4%
Total Long-Term Assets	$155.0M	-$384.1M	$125.1M
YoY Change	23.9%		592.06%
TOTAL ASSETS
Total Short-Term Assets	$774.4M	$429.7M	$480.8M
Total Long-Term Assets	$155.0M	-$384.1M	$125.1M
Total Assets	$929.3M	$45.60M	$605.9M
YoY Change	53.38%		387.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.709M	$13.51M	$13.03M
YoY Change	-63.85%		48.18%
Accrued Expenses	$92.30M	$36.10M	$30.00M
YoY Change	207.67%
Deferred Revenue	$4.472M	$3.394M	$3.297M
YoY Change	35.64%		37.66%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$9.882M
YoY Change	-100.0%		136.02%
Total Short-Term Liabilities	$118.1M	$59.07M	$63.05M
YoY Change	87.36%		94.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$19.84M
YoY Change	-100.0%		-22.17%
Other Long-Term Liabilities	$3.930M	$1.545M	$1.925M
YoY Change	104.16%		149.68%
Total Long-Term Liabilities	$3.930M	$1.545M	$21.76M
YoY Change	-81.94%		-17.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$118.1M	$59.07M	$63.05M
Total Long-Term Liabilities	$3.930M	$1.545M	$21.76M
Total Liabilities	$190.3M	$78.14M	$185.8M
YoY Change	2.38%		83.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$805.1M	-$283.5M	-$262.4M
YoY Change	206.86%		13.52%
Common Stock	$1.544B	$692.6M	$682.5M
YoY Change	126.26%		6012.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$739.1M	$409.1M	$420.1M
YoY Change
Total Liabilities & Shareholders Equity	$929.3M	$610.4M	$605.9M
YoY Change	53.38%		387.43%

Cashflow Statement

Concept	2020 Q4	2020 Q1	2019 Q4
OPERATING ACTIVITIES
Net Income	-$415.6M	-$21.14M	-$7.134M
YoY Change	5725.62%	481.49%	-90.55%
Depreciation, Depletion And Amortization	$3.920M	$3.189M	$2.850M
YoY Change	37.54%	207.82%	220.22%
Cash From Operating Activities	-$130.2M	-$2.576M	$6.700M
YoY Change	-2042.99%	-127.65%	-113.14%
INVESTING ACTIVITIES
Capital Expenditures	-$22.26M	$8.079M	-$6.580M
YoY Change	238.3%	-13.75%	132.51%
Acquisitions		$0.00
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$22.26M	-$8.079M	-$6.580M
YoY Change	238.3%	-13.75%	132.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$31.26M
YoY Change
Cash From Financing Activities	7.710M	-$33.82M	-1.110M
YoY Change	-794.59%	-3764.03%	-103.09%
NET CHANGE
Cash From Operating Activities	-130.2M	-$2.576M	6.700M
Cash From Investing Activities	-22.26M	-$8.079M	-6.580M
Cash From Financing Activities	7.710M	-$33.82M	-1.110M
Net Change In Cash	-144.7M	-$44.59M	-990.0K
YoY Change	14519.19%	-5213.53%	-94.48%
FREE CASH FLOW
Cash From Operating Activities	-$130.2M	-$2.576M	$6.700M
Capital Expenditures	-$22.26M	$8.079M	-$6.580M
Free Cash Flow	-$107.9M	-$10.66M	$13.28M
YoY Change	-912.65%	21644.9%	-127.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001770787
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39035
CY2020	dei	Entity Registrant Name EntityRegistrantName	10x Genomics, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5614458
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	6230 Stoneridge Mall Road
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
CY2020	dei	City Area Code CityAreaCode	(925)
CY2020	dei	Local Phone Number LocalPhoneNumber	401-7300
CY2020	dei	Security12b Title Security12bTitle	Class A common stock, par value $0.00001 per share
CY2020	dei	Trading Symbol TradingSymbol	TXG
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	7300000000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	663603000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	424166000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16567000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51208000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33371000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	29959000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	15270000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13029000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8033000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	774366000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	480840000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72840000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48821000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8474000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	52327000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46983000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26678000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23935000	USD
CY2020Q4	us-gaap	Assets Assets	929341000	USD
CY2019Q4	us-gaap	Assets Assets	605923000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	44173000	USD
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4709000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13028000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15383000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12394000	USD
CY2020Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	43453000	USD
CY2019Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	24448000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9882000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4472000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3297000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5936000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118126000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	63049000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19837000	USD
CY2020Q4	txg	Accrued Contingent Liabilities Noncurrent AccruedContingentLiabilitiesNoncurrent	0	USD
CY2019Q4	txg	Accrued Contingent Liabilities Noncurrent AccruedContingentLiabilitiesNoncurrent	68658000	USD
CY2020Q4	txg	License Fees Accrued Noncurrent LicenseFeesAccruedNoncurrent	11171000	USD
CY2019Q4	txg	License Fees Accrued Noncurrent LicenseFeesAccruedNoncurrent	16251000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	16120000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57042000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3930000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1925000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	190269000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	185840000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108485909	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108485909	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96241596	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96241596	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1544218000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	682494000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805098000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262367000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-46000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	739072000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	420083000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	929341000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	605923000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	146313000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	58468000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	61033000	USD
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	28661000	USD
CY2020	us-gaap	Gross Profit GrossProfit	240377000	USD
CY2019	us-gaap	Gross Profit GrossProfit	184860000	USD
CY2018	us-gaap	Gross Profit GrossProfit	117652000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	123375000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	83097000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	47537000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	447548000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	62363000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	202326000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	130834000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	87936000	USD
CY2020	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1270000	USD
CY2019	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1502000	USD
CY2018	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	30580000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	774519000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	215433000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	228416000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-534142000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-30573000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-110764000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1532000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2805000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1024000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1682000	USD
CY2019	us-gaap	Interest Expense InterestExpense	3079000	USD
CY2018	us-gaap	Interest Expense InterestExpense	2409000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1337000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-186000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-249000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1521000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-334000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-460000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1634000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534476000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31033000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-112398000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8255000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-542735000	USD
CY2020Q2	txg	Number Of Petitions For Inter Partes Review NumberOfPetitionsForInterPartesReview	4	petition
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31260000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-112507000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.37
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.40
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101151675	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101151675	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39091366	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13392273	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-112509000	USD
CY2018	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	256000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2658000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-219987000	USD
CY2019	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	494000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13333000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	420083000	USD
CY2020	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	247000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49467000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	739072000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14012000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7066000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3905000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	48626000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	13333000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2658000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5009000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2018	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1521000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	306000000	USD
CY2019	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2018	us-gaap	Other Noncash Expense OtherNoncashExpense	792000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-614000	USD
CY2020Q2	txg	Number Of Petitions For Inter Partes Review NumberOfPetitionsForInterPartesReview	2	petition
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-251000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	101000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	455000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17847000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5284000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14747000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14601000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6699000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3732000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5265000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3535000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2429000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2686000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	251000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	999000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7770000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4901000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2587000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2936000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5292000	USD
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2600000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2023000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	634000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1673000	USD
CY2020	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	-24485000	USD
CY2019	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	30658000	USD
CY2018	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	38000000	USD
CY2020	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	25917000	USD
CY2019	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	5771000	USD
CY2018	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	1701000	USD
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	12730000	USD
CY2018	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	3328000	USD
CY2020	txg	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4832000	USD
CY2019	txg	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2018	txg	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3771000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	547000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	33000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-217898000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34627000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76409000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36666000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42742000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6284000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1728000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	425000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38394000	USD
CY2020Q3	txg	Number Of Petitions For Inter Partes Review NumberOfPetitionsForInterPartesReview	2	petition
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42767000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6709000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19512000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	31256000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	704000	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	11000000	USD
CY2018	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	11000000	USD
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5848000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	txg	Payments On Capital Lease Obligations PaymentsOnCapitalLeaseObligations	0	USD
CY2019	txg	Payments On Capital Lease Obligations PaymentsOnCapitalLeaseObligations	0	USD
CY2018	txg	Payments On Capital Lease Obligations PaymentsOnCapitalLeaseObligations	69000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	482267000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	410824000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	84830000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23743000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3766000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1798000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	468906000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	414590000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105367000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-463000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	212151000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	406405000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22231000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70088000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47857000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70088000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1670000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2250000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1824000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	280000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	22000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2983000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4492000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2260000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13562000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	243244000	USD
CY2018	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	0	USD
CY2019	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	22099000	USD
CY2018	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	0	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	25041000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	52327000	USD
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	5008000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, loss contingencies, accounting for assets acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.</span></div>
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16600000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	663603000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	424166000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65080000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70088000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents are primarily held with a large financial institution in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of this financial institution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced significant credit losses to date. For the years ended December 31, 2020, 2019, and 2018, no single customer represented more than 10% of revenue. As of December 31, 2020 and December 31, 2019, no single customer represented more than 10% of the Company’s outstanding accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all the Company’s long-lived assets are located in the United States.</span></div>
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1380000	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	txg	Revenue From Contract With Customer Payment Period RevenueFromContractWithCustomerPaymentPeriod	P45D
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38005000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7599000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1900000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1500000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	700000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1300000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	100000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-300000	USD
CY2020Q1	us-gaap	Assets Assets	45604000	USD
CY2020Q1	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	24349000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3086000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50704000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	78139000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	9930000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	6436000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9312000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3996000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10717000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4838000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	29959000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	15270000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	103342000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	67876000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30502000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19055000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72840000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48821000	USD
CY2020	us-gaap	Depreciation Depreciation	12300000	USD
CY2019	us-gaap	Depreciation Depreciation	6700000	USD
CY2018	us-gaap	Depreciation Depreciation	3800000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24641000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2287000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22354000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	22912000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	546000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22366000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1939000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1908000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1828000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1664000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	13015000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22354000	USD
CY2019Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	182000	USD
CY2020Q4	txg	Accrued Payroll And Related Costs AccruedPayrollAndRelatedCosts	2506000	USD
CY2019Q4	txg	Accrued Payroll And Related Costs AccruedPayrollAndRelatedCosts	470000	USD
CY2020Q4	txg	Employee Stock Purchase Program Liability EmployeeStockPurchaseProgramLiability	1258000	USD
CY2019Q4	txg	Employee Stock Purchase Program Liability EmployeeStockPurchaseProgramLiability	1862000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5058000	USD
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6154000	USD
CY2020Q4	txg	Accrued Commissions Current AccruedCommissionsCurrent	3038000	USD
CY2019Q4	txg	Accrued Commissions Current AccruedCommissionsCurrent	2473000	USD
CY2020Q4	txg	Accrued Acquisition Related Compensation Current AccruedAcquisitionRelatedCompensationCurrent	2213000	USD
CY2019Q4	txg	Accrued Acquisition Related Compensation Current AccruedAcquisitionRelatedCompensationCurrent	818000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1035000	USD
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	435000	USD
CY2020Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	275000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15383000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12394000	USD
CY2020Q4	txg	Accrued Legal And Related Expenses Current AccruedLegalAndRelatedExpensesCurrent	5704000	USD
CY2019Q4	txg	Accrued Legal And Related Expenses Current AccruedLegalAndRelatedExpensesCurrent	4888000	USD
CY2020Q4	txg	Accrued License Fees Current AccruedLicenseFeesCurrent	6198000	USD
CY2019Q4	txg	Accrued License Fees Current AccruedLicenseFeesCurrent	6183000	USD
CY2020Q4	txg	Accrued Purchase Consideration Current AccruedPurchaseConsiderationCurrent	4146000	USD
CY2019Q4	txg	Accrued Purchase Consideration Current AccruedPurchaseConsiderationCurrent	0	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3160000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2025000	USD
CY2020Q4	txg	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	2983000	USD
CY2019Q4	txg	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	3885000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3137000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	399000	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	467000	USD
CY2020Q4	txg	Customer Deposits Liability Current CustomerDepositsLiabilityCurrent	1727000	USD
CY2019Q4	txg	Customer Deposits Liability Current CustomerDepositsLiabilityCurrent	1304000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8649000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1087000	USD
CY2020Q4	txg	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	1506000	USD
CY2019Q4	txg	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	534000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5844000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2695000	USD
CY2020Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	43453000	USD
CY2019Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	24448000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	467000	USD
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	804000	USD
CY2020	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	796000	USD
CY2019	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	741000	USD
CY2020	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	864000	USD
CY2019	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1078000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	399000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	467000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6200000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.73
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4500000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4131000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3497000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3295000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2250000	USD
CY2020	txg	Contract With Customer Liability Increase Excluding Revenue Recognized ContractWithCustomerLiabilityIncreaseExcludingRevenueRecognized	5318000	USD
CY2019	txg	Contract With Customer Liability Increase Excluding Revenue Recognized ContractWithCustomerLiabilityIncreaseExcludingRevenueRecognized	2884000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6154000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4131000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	146313000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	146313000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534476000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31033000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8300000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-112240000	USD
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-6517000	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-16653000	USD
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-2958000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	9453000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2684000	USD
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	41253000	USD
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	101000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-52070000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1032000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	99034000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	10783000	USD
CY2020	txg	Income Tax Reconciliation Acquisition Related Expenses IncomeTaxReconciliationAcquisitionRelatedExpenses	93407000	USD
CY2019	txg	Income Tax Reconciliation Acquisition Related Expenses IncomeTaxReconciliationAcquisitionRelatedExpenses	116000	USD
CY2020	txg	Effective Income Tax Rate Reconciliation Change Tax Status Amount EffectiveIncomeTaxRateReconciliationChangeTaxStatusAmount	-34731000	USD
CY2019	txg	Effective Income Tax Rate Reconciliation Change Tax Status Amount EffectiveIncomeTaxRateReconciliationChangeTaxStatusAmount	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-292000	USD
CY2019Q4	txg	Number Of Petitions For Inter Partes Review NumberOfPetitionsForInterPartesReview	4	petition
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	345000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8255000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90562000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28878000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	31908000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15961000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	14392000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	23804000	USD
CY2020Q4	txg	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14192000	USD
CY2019Q4	txg	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	43261000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1339000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6601000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1427000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	200916000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71409000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	186853000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66456000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14063000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4953000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3750000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4946000	USD
CY2020Q4	txg	Deferred Tax Liability Operating Right Of Use Assets DeferredTaxLiabilityOperatingRightOfUseAssets	10388000	USD
CY2019Q4	txg	Deferred Tax Liability Operating Right Of Use Assets DeferredTaxLiabilityOperatingRightOfUseAssets	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14138000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4946000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	75000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	120400000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10800000	USD
CY2013Q4	txg	Operating Loss Carryforwards Limitation Amount OperatingLossCarryforwardsLimitationAmount	4800000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6410000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4169000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	311000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8558000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2241000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14657000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6410000	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	1000000.0	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	10200000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	8400000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	400000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	7100000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9082000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9363000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8863000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8083000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8203000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	34864000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	78458000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15480000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62978000	USD
CY2020Q4	txg	Operating Lease Current Liability OperatingLeaseCurrentLiability	5936000	USD
CY2020Q4	txg	Operating Lease Noncurrent Liability OperatingLeaseNoncurrentLiability	57042000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6247000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7581000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6794000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6947000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7064000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	38346000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	72979000	USD
CY2020Q4	txg	Number Of Petitions For Inter Partes Review NumberOfPetitionsForInterPartesReview	2	petition
CY2020Q2	txg	Payment Of Litigation Settlement Expense PaymentOfLitigationSettlementExpense	2800000	EUR
CY2020Q4	txg	Shares Of Capital Stock Authorized SharesOfCapitalStockAuthorized	1200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108485909	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108485909	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96241596	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96241596	shares
CY2020Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	247000	USD
CY2019Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	494000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	963054	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	78.94
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	123734	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	66.92
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	15373	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	66.71
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	823947	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	80.97
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-112485000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48626000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13333000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2658000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101151675	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101151675	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39091366	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13392273	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.37
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.40
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13000964	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16112652	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82467503	shares

Files In Submission

Name	View Source	Status
0001770787-21-000009-index-headers.html	Edgar Link	pending
0001770787-21-000009-index.html	Edgar Link	pending
0001770787-21-000009.txt	Edgar Link	pending
0001770787-21-000009-xbrl.zip	Edgar Link	pending
a1010-nonqualifiedstocko.htm	Edgar Link	pending
a1010-nonqualifiedstocko001.jpg	Edgar Link	pending
a1010-nonqualifiedstocko002.jpg	Edgar Link	pending
a1010-nonqualifiedstocko003.jpg	Edgar Link	pending
a1010-nonqualifiedstocko004.jpg	Edgar Link	pending
a1010-nonqualifiedstocko005.jpg	Edgar Link	pending
a1010-nonqualifiedstocko006.jpg	Edgar Link	pending
a1010-nonqualifiedstocko007.jpg	Edgar Link	pending
a1010-nonqualifiedstocko008.jpg	Edgar Link	pending
a1010-nonqualifiedstocko009.jpg	Edgar Link	pending
a1010-nonqualifiedstocko010.jpg	Edgar Link	pending
a1010-nonqualifiedstocko011.jpg	Edgar Link	pending
a1011-nonqualifiedstocko.htm	Edgar Link	pending
a1011-nonqualifiedstocko001.jpg	Edgar Link	pending
a1011-nonqualifiedstocko002.jpg	Edgar Link	pending
a1011-nonqualifiedstocko003.jpg	Edgar Link	pending
a1011-nonqualifiedstocko004.jpg	Edgar Link	pending
a1011-nonqualifiedstocko005.jpg	Edgar Link	pending
a1011-nonqualifiedstocko006.jpg	Edgar Link	pending
a1011-nonqualifiedstocko007.jpg	Edgar Link	pending
a1011-nonqualifiedstocko008.jpg	Edgar Link	pending
a1011-nonqualifiedstocko009.jpg	Edgar Link	pending
a1011-nonqualifiedstocko010.jpg	Edgar Link	pending
a1011-nonqualifiedstocko011.jpg	Edgar Link	pending
a1011-nonqualifiedstocko012.jpg	Edgar Link	pending
a1011-nonqualifiedstocko013.jpg	Edgar Link	pending
a1011-nonqualifiedstocko014.jpg	Edgar Link	pending
a1011-nonqualifiedstocko015.jpg	Edgar Link	pending
a1011-nonqualifiedstocko016.jpg	Edgar Link	pending
a1011-nonqualifiedstocko017.jpg	Edgar Link	pending
a1011-nonqualifiedstocko018.jpg	Edgar Link	pending
a1011-nonqualifiedstocko019.jpg	Edgar Link	pending
a1011-nonqualifiedstocko020.jpg	Edgar Link	pending
a1011-nonqualifiedstocko021.jpg	Edgar Link	pending
a1011-nonqualifiedstocko022.jpg	Edgar Link	pending
a1011-nonqualifiedstocko023.jpg	Edgar Link	pending
a1011-nonqualifiedstocko024.jpg	Edgar Link	pending
a1011-nonqualifiedstocko025.jpg	Edgar Link	pending
a106-readcoormergeragree.htm	Edgar Link	pending
a106-readcoormergeragree001.jpg	Edgar Link	pending
a106-readcoormergeragree002.jpg	Edgar Link	pending
a106-readcoormergeragree003.jpg	Edgar Link	pending
a106-readcoormergeragree004.jpg	Edgar Link	pending
a106-readcoormergeragree005.jpg	Edgar Link	pending
a106-readcoormergeragree006.jpg	Edgar Link	pending
a106-readcoormergeragree007.jpg	Edgar Link	pending
a106-readcoormergeragree008.jpg	Edgar Link	pending
a106-readcoormergeragree009.jpg	Edgar Link	pending
a106-readcoormergeragree010.jpg	Edgar Link	pending
a106-readcoormergeragree011.jpg	Edgar Link	pending
a106-readcoormergeragree012.jpg	Edgar Link	pending
a106-readcoormergeragree013.jpg	Edgar Link	pending
a106-readcoormergeragree014.jpg	Edgar Link	pending
a106-readcoormergeragree015.jpg	Edgar Link	pending
a106-readcoormergeragree016.jpg	Edgar Link	pending
a106-readcoormergeragree017.jpg	Edgar Link	pending
a106-readcoormergeragree018.jpg	Edgar Link	pending
a106-readcoormergeragree019.jpg	Edgar Link	pending
a106-readcoormergeragree020.jpg	Edgar Link	pending
a106-readcoormergeragree021.jpg	Edgar Link	pending
a106-readcoormergeragree022.jpg	Edgar Link	pending
a106-readcoormergeragree023.jpg	Edgar Link	pending
a106-readcoormergeragree024.jpg	Edgar Link	pending
a106-readcoormergeragree025.jpg	Edgar Link	pending
a106-readcoormergeragree026.jpg	Edgar Link	pending
a106-readcoormergeragree027.jpg	Edgar Link	pending
a106-readcoormergeragree028.jpg	Edgar Link	pending
a106-readcoormergeragree029.jpg	Edgar Link	pending
a106-readcoormergeragree030.jpg	Edgar Link	pending
a106-readcoormergeragree031.jpg	Edgar Link	pending
a106-readcoormergeragree032.jpg	Edgar Link	pending
a106-readcoormergeragree033.jpg	Edgar Link	pending
a106-readcoormergeragree034.jpg	Edgar Link	pending
a106-readcoormergeragree035.jpg	Edgar Link	pending
a106-readcoormergeragree036.jpg	Edgar Link	pending
a106-readcoormergeragree037.jpg	Edgar Link	pending
a106-readcoormergeragree038.jpg	Edgar Link	pending
a106-readcoormergeragree039.jpg	Edgar Link	pending
a106-readcoormergeragree040.jpg	Edgar Link	pending
a106-readcoormergeragree041.jpg	Edgar Link	pending
a106-readcoormergeragree042.jpg	Edgar Link	pending
a106-readcoormergeragree043.jpg	Edgar Link	pending
a106-readcoormergeragree044.jpg	Edgar Link	pending
a106-readcoormergeragree045.jpg	Edgar Link	pending
a106-readcoormergeragree046.jpg	Edgar Link	pending
a106-readcoormergeragree047.jpg	Edgar Link	pending
a106-readcoormergeragree048.jpg	Edgar Link	pending
a106-readcoormergeragree049.jpg	Edgar Link	pending
a106-readcoormergeragree050.jpg	Edgar Link	pending
a106-readcoormergeragree051.jpg	Edgar Link	pending
a106-readcoormergeragree052.jpg	Edgar Link	pending
a106-readcoormergeragree053.jpg	Edgar Link	pending
a106-readcoormergeragree054.jpg	Edgar Link	pending
a106-readcoormergeragree055.jpg	Edgar Link	pending
a106-readcoormergeragree056.jpg	Edgar Link	pending
a106-readcoormergeragree057.jpg	Edgar Link	pending
a106-readcoormergeragree058.jpg	Edgar Link	pending
a106-readcoormergeragree059.jpg	Edgar Link	pending
a106-readcoormergeragree060.jpg	Edgar Link	pending
a106-readcoormergeragree061.jpg	Edgar Link	pending
a106-readcoormergeragree062.jpg	Edgar Link	pending
a106-readcoormergeragree063.jpg	Edgar Link	pending
a106-readcoormergeragree064.jpg	Edgar Link	pending
a106-readcoormergeragree065.jpg	Edgar Link	pending
a106-readcoormergeragree066.jpg	Edgar Link	pending
a106-readcoormergeragree067.jpg	Edgar Link	pending
a106-readcoormergeragree068.jpg	Edgar Link	pending
a106-readcoormergeragree069.jpg	Edgar Link	pending
a106-readcoormergeragree070.jpg	Edgar Link	pending
a106-readcoormergeragree071.jpg	Edgar Link	pending
a106-readcoormergeragree072.jpg	Edgar Link	pending
a106-readcoormergeragree073.jpg	Edgar Link	pending
a106-readcoormergeragree074.jpg	Edgar Link	pending
a106-readcoormergeragree075.jpg	Edgar Link	pending
a106-readcoormergeragree076.jpg	Edgar Link	pending
a106-readcoormergeragree077.jpg	Edgar Link	pending
a106-readcoormergeragree078.jpg	Edgar Link	pending
a106-readcoormergeragree079.jpg	Edgar Link	pending
a106-readcoormergeragree080.jpg	Edgar Link	pending
a106-readcoormergeragree081.jpg	Edgar Link	pending
a106-readcoormergeragree082.jpg	Edgar Link	pending
a106-readcoormergeragree083.jpg	Edgar Link	pending
a106-readcoormergeragree084.jpg	Edgar Link	pending
a106-readcoormergeragree085.jpg	Edgar Link	pending
a106-readcoormergeragree086.jpg	Edgar Link	pending
a106-readcoormergeragree087.jpg	Edgar Link	pending
a106-readcoormergeragree088.jpg	Edgar Link	pending
a106-readcoormergeragree089.jpg	Edgar Link	pending
a106-readcoormergeragree090.jpg	Edgar Link	pending
a106-readcoormergeragree091.jpg	Edgar Link	pending
a106-readcoormergeragree092.jpg	Edgar Link	pending
a106-readcoormergeragree093.jpg	Edgar Link	pending
a106-readcoormergeragree094.jpg	Edgar Link	pending
a106-readcoormergeragree095.jpg	Edgar Link	pending
a106-readcoormergeragree096.jpg	Edgar Link	pending
a107-restrictedstockunit.htm	Edgar Link	pending
a107-restrictedstockunit001.jpg	Edgar Link	pending
a107-restrictedstockunit002.jpg	Edgar Link	pending
a107-restrictedstockunit003.jpg	Edgar Link	pending
a107-restrictedstockunit004.jpg	Edgar Link	pending
a107-restrictedstockunit005.jpg	Edgar Link	pending
a107-restrictedstockunit006.jpg	Edgar Link	pending
a107-restrictedstockunit007.jpg	Edgar Link	pending
a107-restrictedstockunit008.jpg	Edgar Link	pending
a107-restrictedstockunit009.jpg	Edgar Link	pending
a107-restrictedstockunit010.jpg	Edgar Link	pending
a107-restrictedstockunit011.jpg	Edgar Link	pending
a107-restrictedstockunit012.jpg	Edgar Link	pending
a107-restrictedstockunit013.jpg	Edgar Link	pending
a107-restrictedstockunit014.jpg	Edgar Link	pending
a107-restrictedstockunit015.jpg	Edgar Link	pending
a107-restrictedstockunit016.jpg	Edgar Link	pending
a107-restrictedstockunit017.jpg	Edgar Link	pending
a107-restrictedstockunit018.jpg	Edgar Link	pending
a107-restrictedstockunit019.jpg	Edgar Link	pending
a107-restrictedstockunit020.jpg	Edgar Link	pending
a107-restrictedstockunit021.jpg	Edgar Link	pending
a107-restrictedstockunit022.jpg	Edgar Link	pending
a107-restrictedstockunit023.jpg	Edgar Link	pending
a107-restrictedstockunit024.jpg	Edgar Link	pending
a107-restrictedstockunit025.jpg	Edgar Link	pending
a107-restrictedstockunit026.jpg	Edgar Link	pending
a107-restrictedstockunit027.jpg	Edgar Link	pending
a107-restrictedstockunit028.jpg	Edgar Link	pending
a108-incentivestockoptio.htm	Edgar Link	pending
a108-incentivestockoptio001.jpg	Edgar Link	pending
a108-incentivestockoptio002.jpg	Edgar Link	pending
a108-incentivestockoptio003.jpg	Edgar Link	pending
a108-incentivestockoptio004.jpg	Edgar Link	pending
a108-incentivestockoptio005.jpg	Edgar Link	pending
a108-incentivestockoptio006.jpg	Edgar Link	pending
a108-incentivestockoptio007.jpg	Edgar Link	pending
a108-incentivestockoptio008.jpg	Edgar Link	pending
a108-incentivestockoptio009.jpg	Edgar Link	pending
a108-incentivestockoptio010.jpg	Edgar Link	pending
a108-incentivestockoptio011.jpg	Edgar Link	pending
a109-nonqualifiedstockop.htm	Edgar Link	pending
a109-nonqualifiedstockop001.jpg	Edgar Link	pending
a109-nonqualifiedstockop002.jpg	Edgar Link	pending
a109-nonqualifiedstockop003.jpg	Edgar Link	pending
a109-nonqualifiedstockop004.jpg	Edgar Link	pending
a109-nonqualifiedstockop005.jpg	Edgar Link	pending
a109-nonqualifiedstockop006.jpg	Edgar Link	pending
a109-nonqualifiedstockop007.jpg	Edgar Link	pending
a109-nonqualifiedstockop008.jpg	Edgar Link	pending
a109-nonqualifiedstockop009.jpg	Edgar Link	pending
a109-nonqualifiedstockop010.jpg	Edgar Link	pending
a231_eyconsent.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
txg-20201231.htm	Edgar Link	pending
txg-20201231.xsd	Edgar Link	pending
txg-20201231xex311.htm	Edgar Link	pending
txg-20201231xex312.htm	Edgar Link	pending
txg-20201231xex321.htm	Edgar Link	pending
txg-20201231xex322.htm	Edgar Link	pending
txg-20201231_cal.xml	Edgar Link	unprocessable
txg-20201231_def.xml	Edgar Link	unprocessable
txg-20201231_g1.jpg	Edgar Link	pending
txg-20201231_g10.jpg	Edgar Link	pending
txg-20201231_g11.jpg	Edgar Link	pending
txg-20201231_g2.jpg	Edgar Link	pending
txg-20201231_g3.jpg	Edgar Link	pending
txg-20201231_g4.jpg	Edgar Link	pending
txg-20201231_g5.jpg	Edgar Link	pending
txg-20201231_g6.jpg	Edgar Link	pending
txg-20201231_g7.jpg	Edgar Link	pending
txg-20201231_g8.jpg	Edgar Link	pending
txg-20201231_g9.jpg	Edgar Link	pending
txg-20201231_htm.xml	Edgar Link	completed
txg-20201231_lab.xml	Edgar Link	unprocessable
txg-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TXG
10X Genomics Inc Stock $txg

2020 Q4 Form 10-K Financial Statement

#000177078721000009 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXG 10X Genomics Inc Stock $txg

2020 Q4 Form 10-K Financial Statement

#000177078721000009 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXG
10X Genomics Inc Stock $txg